Feverfew extract (parthenolide)
Chronic Myeloid Leukemia - CML
Important notice: You must inform your CML doctor or a qualified doctor if you want to take feverfew (parthenolide) or other product. The material presented here is for information purposes only; it is not a substitute for your physician’s guidance and care. Feverfew may increase the risk of bleeding when used with anticoagulants (blood thinners) or anti-platelet drugs. It is not recommended for use in patients undergoing surgery. Feverfew is not recommended for use by pregnant or lactating women, or children under two years of age.
Cautions ( Extract of Feverfew and Cancer)
''The label cautions that feverfew is not recommended for use by pregnant or lactating women, or children under two years of age. Certain individuals may also experience oral discomfort or irritation when using the product. If irritation does occur, the manufacturer advises discontinuing the use of the product immediately. According to the website www.intelihealth.com:
Feverfew has been well tolerated in studies. The most common side effects are mouth inflammation or ulcers, including swelling of the lips, bleeding of the gums, and loss of taste. When stopped suddenly after being used for long periods of time, feverfew may cause rebound headaches, anxiety, sleep disturbances, muscle stiffness or pain. Some people may experience more rapid or pounding heart rates. Skin irritation or eczema may occur in those with feverfew allergies. Photosensitivity (sensitivity to sunlight or sunlamps) has been reported with other herbs in the Compositae plant family and may be possible with feverfew as well. Less common side effects may include stomach upset, such as indigestion, nausea, gas, constipation, diarrhea, bloating or heartburn.
It is not at all clear how often these adverse events occur. The website further cautions that feverfew may combine adversely with certain drugs:
In theory, feverfew may increase the risk of bleeding when used with anticoagulants (blood thinners) or anti-platelet drugs. Examples include warfarin (Coumadin), heparin and clopidogrel (Plavix). Feverfew may also increase the risk of bleeding when used with anti-inflammatory pain relievers, such as aspirin, ibuprofen (Motrin, Advil) and naproxen (Naprosyn, Aleve, Anaprox). However, it is possible that feverfew may increase the effectiveness of these pain relievers.
"Based on the results from some animal studies, it has been suggested that feverfew could worsen symptoms of depression or reduce the effectiveness of antidepressants such as fluoxetine (Prozac). Feverfew should be used with caution in individuals with a history of depression or other psychiatric illnesses.''
ARTICLES
Targeting acute myeloid leukemia stem cell signaling by natural products
January 30, 2017, PublMed
Parthenolide and DMAPT Induce Cell Death in Chronic Myeloid Leukemia Cells Via Generation of Reactive Oxygen Species
2016, Journal Blood
In vivo targeting of leukemia stem cells by directing parthenolide-loaded nanoparticles to the bone marrow niche
July 30, 2016, NCBI
IKK-dependent activation of NF-κB contributes to myeloid and lymphoid leukemogenesis by BCR-ABL1
April 10, 2014, Journal Blood
Inhibition of intracellular dipeptidyl peptidases 8 and 9 enhances parthenolide’s anti-leukemic activity
February 8, 2013, Leukemia
Parthenolide eliminates leukemia initiating cell populations and improves survival in xenografts of childhood acute lymphoblastic leukemia
December 20, 2012, Blood Journal
Parthenolide, a Sesquiterpene Lactone, Expresses Mutiple Anti-cancer and anti-inflammatory Activities
May 21, 2011, Scribd
Parthenolide treatment activates stress signaling proteins in high-risk acute lymphoblastic leukemia cells with chromosomal translocation t(4;11)
November 2011, International Journal of Oncology
Chemical genomic screening reveals synergism between parthenolide and inhibitors of the PI-3 kinase and mTOR pathways
September 10, 2010, Journal Blood
Discovery of agents that eradicate leukemia stem cells using an in silico screen of public gene expression data.
June 15, 2008, PubLMed
An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells
December 15,2007, Journal Blood
New Leukemia Drug Stems From Feverfew
October 3, 2007, Medical News Today
Parthenolide Analog-Blood Cancer Clinical Trial Soon To Begin In England
October 3, 2007, Margaret's Corner
Feverfew: weeding out the root of leukaemia.
September 5, 2005, PublMed
Chemical in Feverfew Plant May Fight Leukemia
February 25, 2005, WebMD Health News
Feverfew or Bachelor's Button, kills human leukemia stem cells like no other single therapy
February 23, 2005, News Medical
Plant derivative attacks the roots of leukemia
February 23, 2005, EurekAlert
Feverfew compound gets at leukemia roots
February 23, 2005, Wikinews
Phase I dose escalation trial of feverfew with standardized doses of parthenolide in patients with cancer.
August 22, 2004, PublMed
Targeting acute myeloid leukemia stem cell signaling by natural products
January 30, 2017, PublMed
Parthenolide and DMAPT Induce Cell Death in Chronic Myeloid Leukemia Cells Via Generation of Reactive Oxygen Species
2016, Journal Blood
In vivo targeting of leukemia stem cells by directing parthenolide-loaded nanoparticles to the bone marrow niche
July 30, 2016, NCBI
IKK-dependent activation of NF-κB contributes to myeloid and lymphoid leukemogenesis by BCR-ABL1
April 10, 2014, Journal Blood
Inhibition of intracellular dipeptidyl peptidases 8 and 9 enhances parthenolide’s anti-leukemic activity
February 8, 2013, Leukemia
Parthenolide eliminates leukemia initiating cell populations and improves survival in xenografts of childhood acute lymphoblastic leukemia
December 20, 2012, Blood Journal
Parthenolide, a Sesquiterpene Lactone, Expresses Mutiple Anti-cancer and anti-inflammatory Activities
May 21, 2011, Scribd
Parthenolide treatment activates stress signaling proteins in high-risk acute lymphoblastic leukemia cells with chromosomal translocation t(4;11)
November 2011, International Journal of Oncology
Chemical genomic screening reveals synergism between parthenolide and inhibitors of the PI-3 kinase and mTOR pathways
September 10, 2010, Journal Blood
Discovery of agents that eradicate leukemia stem cells using an in silico screen of public gene expression data.
June 15, 2008, PubLMed
An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells
December 15,2007, Journal Blood
New Leukemia Drug Stems From Feverfew
October 3, 2007, Medical News Today
Parthenolide Analog-Blood Cancer Clinical Trial Soon To Begin In England
October 3, 2007, Margaret's Corner
Feverfew: weeding out the root of leukaemia.
September 5, 2005, PublMed
Chemical in Feverfew Plant May Fight Leukemia
February 25, 2005, WebMD Health News
Feverfew or Bachelor's Button, kills human leukemia stem cells like no other single therapy
February 23, 2005, News Medical
Plant derivative attacks the roots of leukemia
February 23, 2005, EurekAlert
Feverfew compound gets at leukemia roots
February 23, 2005, Wikinews
Phase I dose escalation trial of feverfew with standardized doses of parthenolide in patients with cancer.
August 22, 2004, PublMed
